HPV Oncogenes Redirect Cisplatin Damage Into a New Repair Dependency
HPV-positive head and neck squamous cell carcinoma does not simply respond better to cisplatin-based chemoradiation because the tumors are easier to kill. The biology is more specific than that. In this preprint, genome-wide CRISPR screening mapped a distinct survival program in HPV+ HNSCC cells, one that bypasses the canonical Fanconi anemia pathway and instead leans on PRIMPOL-driven repriming and post-replicative gap filling after cisplatin-induced DNA crosslinks.
The work matters because current treatment still applies the same chemoradiation backbone to HPV-negative and HPV-positive disease, even though their clinical behavior diverges. Better survival in HPV-positive tumors has long suggested that the lesions themselves, not just the host response, carry a different DNA damage program. Here, the difference is embedded in the way the cells tolerate replication stress after crosslink formation.
One sentence captures the central shift: HPV oncogenes rewire crosslink repair.
Fanconi Pathway Independence Replaces the Usual Crosslink Response
Cisplatin creates interstrand crosslinks that stall replication forks and normally drive dependence on the Fanconi anemia machinery. In the HPV-positive setting, that dependency weakened. The screening data showed that HPV+ cells tolerated cisplatin-induced interstrand crosslinks without relying on the Fanconi anemia pathway, and the same phenotype emerged when HPV16 E6 and HPV16 E7 were expressed in an HPV-negative background.
That experimental design is important because it ties the altered repair logic to the viral oncogenes themselves rather than to unrelated features of the parental line. E6 and E7 are already known to perturb cell-cycle control and genome surveillance, but this study places them directly inside the replication stress response. The implication is straightforward: the viral proteins do not merely accelerate proliferation or dampen checkpoints; they reshape how cells survive crosslink damage at the fork.
The consequence is a repair choice that favors tolerance over faithful resolution. Rather than fully committing to the Fanconi pathway, the damaged fork appears to be reprised past the lesion, leaving behind gaps that must be managed later.
PRIMPOL Repriming Keeps the Fork Moving, But at a Cost
The alternative pathway depends on PRIMPOL, a repriming enzyme that can restart DNA synthesis downstream of a blocking lesion. Biologically, this is a survival tactic with a tradeoff: the cell avoids catastrophic fork collapse in the moment, but it creates stretches of single-stranded DNA that need to be filled in after replication has moved on. Translesion synthesis polymerases then step in to patch these post-replicative gaps.
This arrangement fits the pattern seen in the screens. HPV-positive cells needed PRIMPOL-mediated repriming and downstream gap filling to survive cisplatin stress, which means the viral oncogene state appears to shift repair from lesion removal toward lesion bypass. In a tumor cell, that can be enough to preserve replication through chemotherapy exposure. In therapeutic terms, it also opens a narrow vulnerability: remove the bypass support and the damage becomes lethal.
BRCA1, a central organizer of homologous recombination and fork protection, remained part of the picture but behaved differently depending on the DNA substrate. Recruitment to double-strand breaks looked intact, yet BRCA1 accumulation at cisplatin-stalled forks fell sharply. The protein is still available to help at breaks, but its function is uncoupled from the stalled-replication context where crosslink damage is most relevant.
BRCA1 Splits Its Behavior Between Breaks and Stalled Forks
This separation between double-strand break repair and crosslink-stalled fork repair is one of the clearest mechanistic signals in the study. BRCA1 is not globally absent. Instead, its localization is selectively blunted where cisplatin-induced replication stress matters most. That distinction suggests a rewired fork environment in HPV-positive cells, one in which the protein network normally needed to stabilize and process stalled forks is not assembled in the standard way.
A useful clinical analogy is that the same crew shows up to the wrong location. BRCA1 can still respond to break-associated damage, but the cisplatin-stalled fork in HPV-positive cells does not recruit it efficiently. The tumor therefore leans on a different repair architecture, one built around repriming and gap management rather than classical fork protection.
RAD51 Turnover Becomes the Achilles’ Heel
Once PRIMPOL creates single-stranded DNA gaps, the cells become dependent on dynamic RAD51 turnover at those sites. RAD51 is usually thought of as a stabilizer of homologous recombination intermediates, but here its filament dynamics are central to survival. The study shows that disrupting this balance, either by depleting the RAD51 unloading factor FIRRM or by chemically stabilizing RAD51 filaments, selectively killed HPV-positive and HPV-oncogene-expressing cells treated with cisplatin.
The direction of the effect is striking. Too little RAD51 dynamics is harmful, but so is locking RAD51 too tightly in place. Both interventions appear to poison the same tolerance pathway, which depends on controlled assembly and disassembly at post-replicative gaps. When that flux is lost, the cell can no longer complete the repair choreography needed to survive cisplatin exposure.
PRIMPOL depletion reversed the lethality, tying the toxic effect directly back to the repriming pathway. In other words, the vulnerability only exists because the cells first choose the PRIMPOL-dependent escape route. Remove that route and the specific RAD51-associated trap disappears.
A Therapeutic Opening for HPV-Positive Head and Neck Cancer
For HPV-positive HNSCC, this work points toward a strategy that does not rely solely on increasing DNA damage. Instead, it suggests that therapy might be improved by targeting the repair state the tumor uses to endure cisplatin. If HPV oncogenes create dependence on PRIMPOL-mediated lesion bypass and RAD51 filament dynamics, then drugs that interfere with that state could selectively sensitize the tumor while preserving some of the benefit of HPV-driven treatment responsiveness.
The attraction is obvious: a vulnerability linked to the viral oncogenes themselves could help explain why HPV-positive tumors are biologically distinct and potentially more targetable. It also raises the possibility of lowering long-term toxicity if effective sensitization allows for more precise treatment rather than broader intensification. The mechanism is grounded in replication biology, not general tumor weakness.
Because this is a preprint, the findings still need peer review and independent confirmation. The study also remains cellular and mechanistic rather than clinical, so the extent to which the PRIMPOL-RAD51 axis can be exploited in patients with HPV-positive head and neck cancer is unresolved. What is already clear is narrower and more concrete: HPV oncogenes do not merely coexist with cisplatin sensitivity; they reorganize crosslink repair into a PRIMPOL-dependent state that can be turned against the tumor.